A naukri.com initiative
Bioengineer
2w
172
Image Credit: Bioengineer
Ahead-of-Print Highlights from The Journal of Nuclear Medicine – May 23, 2025
- Recently published studies in The Journal of Nuclear Medicine highlight advancements in targeted radiotherapeutic approaches and imaging technologies for cancer therapy.
- Innovative dosimetric models for peptide receptor radionuclide therapy (PRRT) show potential to enhance radiation dose accuracy and treatment efficacy for neuroendocrine tumors.
- A clinical trial on lutetium-177 labeled PSMA-617 for hormone-sensitive prostate cancer demonstrates promising results in reducing cancer biomarkers and delaying disease progression.
- Higher radiation doses via yttrium-90 (⁹⁰Y) glass microspheres improve outcomes for colorectal cancer metastasized to the liver, establishing a dose–response relationship.
- Radium-223 dichloride retreatment offers hope for managing skeletal metastases in prostate cancer, with potential for personalized retreatment schedules for better long-term management.
- Molecular imaging techniques, such as 18F-fluorodeoxyglucose PET/CT scans, provide valuable prognostic biomarkers for neuroendocrine tumors, aiding in treatment stratification.
- Research on ¹⁷⁷Lu-DOTATATE therapy for bone metastases in neuroendocrine tumors highlights significant pain relief and survival benefits, emphasizing dose optimization.
- Development of a new PET radiotracer, ¹⁸F-SITATE, shows promise in enhancing neuroendocrine tumor detection with improved accuracy in staging and treatment planning.
- International studies emphasize the importance of predictive pretreatment PET imaging for renal radiation dose prediction in PRRT, advocating for standardized imaging protocols.
- These advancements signal a shift towards precision medicine in nuclear oncology, enhancing patient outcomes through refined dosimetry and personalized radionuclide therapies.
Read Full Article
10 Likes
For uninterrupted reading, download the app